Fifteen Points about MIAS and how it can help
"Early Cancer Detection
Locates CARCINOGEN Smaller Than 1mm In SIZE Through Radiology &
Medical Imaging Analysis Software By
Medical Imaging Analysis and Diagnosis of MRI, CT, and PET Scans Dr. David Kanecki, MBA, A.C.S., Bio. Sci. Kanecki, Associates, Inc. P.O. Box 866 Kenosha, WI 53141 Description of the Invention The MIAS, medical image analysis system, is able to analyze and diagnosis MRI, CT, and PET scan images to determine the positive areas for cancer and to distinguish between the false positive areas. It has a 95% accuracy rate on single image comparisons, and a 85% accuracy rate on “3 Plane Loc” series. The false positive rate for each is 5% and 10% respectively. *
What is Claimed 1. Ability to determine positive cancerous areas in MRI, CT, and PET scans on a individual slide. 2. Ability to determine positive cancerous areas in MRI, CT, and PET scans on a series as a “3 Plane Loc” series. 3. 95% accuracy rate with a 5% false positive rate for single slide evaluations. 4. 85% accuracy rate with a 10% false positive rate for “3 Plane Loc” evaluations. Discussion
* FIRST RESULTS OF MEDICAL STUDY USING MIAS 60 LABORATORY David Kanecki, MBA, A.C.S., Bio. Sci. Kanecki Associates, Inc., * P.O. Box 866 * Kenosha, WI 53141 * UNITED STATES david@kanecki.com ABSTRACT Based upon initial testing, the MIAS 60 program could be used as a screening program for cancer, and as an assistant for cancer determination. As a screening program, the program has a 95.6% accuracy rate, and as a cancer determination program, it has a 82.4% accuracy rate. In addition, there are no false negatives given as a result. This means that a patient will not be misdiagnosed because of false negative. The screen accuracy range is approximately 92-100%, and the cancer detection range is 65-100 percent. In screening, the program surpasses a human reader, and in cancer detection via a “3 Plane Loc” analysis, it is approximately equal to a human reader. *
This study is being performed at Wheaton Franciscan Hospital of Racine, WI. INTRODUCTION The purpose of this study is to determine the accuracy rate of the MIAS 60 program to detect cancer in patients using a “3 Plane loc” analysis. The study consists of analyzing 300 patient samples, and this report gives results for the first set of 25 patient samples. The MIAS 60 Laboratory program provides an analysis using multiple measurements and generating a single conclusion for an individual slide and the whole series as positive or negative. The conclusion from the whole series is what is important in determining if someone has cancer. The first part of the testing involved calibrating the MIAS 60 Laboratory program along with establishing patient control sets to use a reference. These control sets were selected by the variation of the “3 Plane Loc” process and on comparative anatomy of the scans to provide a close, accurate starting point. Once the control sets were setup, the first experiments were done.
** MATERIALS AND METHODS The first part of performing the medical analysis was to select a set of patients as the reference set for the study. The selected set is references by a notation of gender (f/m), nc (negative control) or pc (positive control), and nc or pc number, i.e. 1. Thus, ‘fnc1’ would indicate that the a female, negative, control one was used for the analysis. The exam use specifies which reference set to use, based upon the variation of the “3 place loc” examination performed. When there is a difference between the predicted result of cancer and the expected result of cancer, a second review is conducted. The second review consists of comparing the patient report for the test, and determining if the symptoms are positive or negative, relative to the two patient samples. A positive designation is given when a patient or patients have symptoms found in two different anatomical areas of the brain. This method is used because all of the patient samples we are based upon the patient having symptoms as left sided weakness, dizziness, blurred vision, etc. Thus, the second review is used to compare conflicting results between the predicted determination by MIAS. Based upon the notation used, the following table shows which patient data we used as control sets: Patient ID Gender Exam Use Cancer Present Notation Name Number of MRI scans P010 F 1 P Fpc1 21 P001 F 1 N Fnc1 15 P004 M 1 N Mnc1 15 P005 F 3 N Fnc3 21 (2 visits) P006 F 1 N Fnc2 42 P007 F 4 N Fnc4 33 P022 M 5 N Mnc2 15 From this sample set, a series of 25 experiments are performed. The goals of the experiments are 1) to determine the accuracy rate of predicting cancer in a MRI test series and 2) to determine the accuracy of recognizing significant, symptom areas that are not cancerous.
The summary of the results are: By Cancer By Symptom Total 23, 100% 23, 100% Correct 19, 82.6% 22, 95.6% False Positive 4, 17.4% 1, 4.3% False Negative 0, 0.0% 0. 0% With the cancer analysis, the program is approximately equal to a human reader, p=0.15 error rate, and the program error rate is p=0.164. *In addition, the program has a false positive rate 17.4% percent which means the reading accuracy can range from 69- 100% accuracy, exceeding a human reader at the upper levels. By having the program issue a false positive and not issue a false negative, this means the program’s error will not result in a missed diagnosis. With the symptoms, the program is better than a human reader with an accuracy rate of 95.6% and an error rate of 4.4%, p=0.044, which is better than p=0.15, our null hypothesis for a human reader. In addition the program has a 4.4% false positive rate which means that it range of accuracy is 91.2% to 100%, which is better than the null hypothesis of a human reader. Therefore, this shows the MIAS can be used for screening along with a secondary review
*** CONCLUSION The results of this study show that the MIAS surpass a human reader for screening, and is approximately equal to a human reader for cancer determination. Since the program does not issue a false positive, the benefit is toward better treatment because a lack of a false negative diagnosis means that a patient is not misdiagnosed where a cancer exists. Based upon these results, the MIAS program could be used as a screening program for cancer, and as an assistant for diagnosing cancer. The patient samples used in this study were supplied by Wheaton Franciscan Hospital of Racine, WI. The medical study is being conducted at the same hospital.
MIAS, Medical Image Analysis System, uses a two dimensional approach to spot cancer. The reason this approach is more accurate and efficient than the three-dimensional approach used today is due to the computers software ability for spotting the cancers location by pixel rating as opposed to someone having to determine an area from a visual contrast. After the individual determines which areas that the fluorescent dyes highlight an assumption is made which runs a risk of human error. The ability to spot the cancer by computer software pixel ratings increases location accuracy and reduced errors in reading radiological CT, MRI, and PET scans. Combined the two test run consistently could solve the problems that exist in radiological diagnosis!
** The Medical Imaging Analysis Software uses a special patented Dicomm File Converter to extract the bipmap files used by all Medical Scanners. Then, a pixel is assigned a value of 0 (black) – 24 MILLION (bright white). A cancer usually is observed on a scan with a value of 150 or over Based upon the statistical value and pixel value a cancer can be detected to an exact location on our grid of 5000 by 5000 pixels The MIAS provides an image of the cancer shape, location, intensity, and many other features to detect cancer smaller than 1mm in size!
*** Imaging Enhancements have the ability for earlier cancer detection less than 1mm sq from modifying the pixel rating from 0-255 to 0-24 million range. This has been done when the program applies ability while reading jpeg files or bitmap files with 24-bit color. Currently, the program works on the 2006 Dicomm standard of a bitmap file of 8-bit grayscale and 24-bit gray scale files that is run on all machines.
Kanecki And Associates Inc. is interested in co-venturing with other medical
scanning companies. Image 4D Systems Upgraded Features! Expected Release: Third Quarter of 2008,
The MIAS 3D and 4D viewer,allows you to view MRI images in three dimensions and in four dimensions by sections. The advantage of this viewer is that you can rotate the 3d and 4d perspectives highlighting the cancer areas. *
This imager will work with MRI, Dicomm based scans of any size. It is designed to work on windows xp and vista first with it being ported to Linux and to Java enabled smart phones. ********************************************************* ********************************************************
The MIAS SMART PHONE/POCKET PC PROJECT FOR JAVA APPLICATIONS Estimated Completion Date: Fourth Quarter 2008 As part of the medical image analysis program, MIAS, this project will use MIAS analysis and results to be performed on a smart phone or pocket pc. This advantage enables the treatment strategy sooner with immediate analysis wherever needed. The smart phone/pocket pc MIAS, Smart MIAS, application will allow the portable aspect of oncologist analysis using secured smart devices. This allows a faster response time since the oncologist can respond directly, and reduced travel time. This project will use MIAS, the Smart MIAS application on the iPhone, iPaq, Nokia, and other smart phone/computer devices. This will allow for the use of mobile and rapid response decision making. Look for the Smart MIAS on December 1st, the fourth quarter of 2008.
Kanecki And Associates Inc. is interested in co-venturing with other medical
scanning companies. Image 4D Systems Upgraded Features! Expected Release: Third Quarter of 2008,
The MIAS
3D and 4D viewer,allows you to view MRI images in three dimensions and in four dimensions by sections. The advantage of this viewer
is that you can rotate the 3d and 4d perspectives highlighting the cancer areas. *** This imager will work with MRI, Dicomm based
scans of any size. It is designed to work on windows xp and vista first with it being ported to Linux and to Java enabled smart phones.
The
MIAS SMART PHONE/POCKET PC PROJECT FOR JAVA APPLICATIONS Estimated Completion Date: Fourth Quarter 2008 As
part of the medical image analysis program, MIAS, this project will use
MIAS analysis and results to be performed on a smart phone or pocket
pc. This advantage enables the treatment strategy sooner with immediate
analysis wherever needed. The smart phone/pocket pc MIAS, Smart MIAS,
application will allow the portable aspect of oncologist analysis using
secured smart devices. This allows a faster response time since the
oncologist can respond directly, and reduced travel time. This project
will use MIAS, the Smart MIAS application on the iPhone, iPaq,
Nokia, and other smart phone/computer devices. This will allow for the
use of mobile and rapid response decision making. Look for the Smart
MIAS on December 1st, the fourth quarter of 2009. *
Java
Questions What is Java? Java is a programming language used on
computers. It is used to program applications and also enhance mobile
phone gaming. What is J2ME? J2ME stands for Java 2 Micro Edition. It is
a Java technology that is designed specifically to work on small
devices like mobile phones, PDAs etc. J2ME applications are delivered
to a mobile phone over the WAP or GPRS network. What is a Java enabled
phone? A Java enabled phone is a phone that allows you to play enhanced
games and use application. (Example: Nokia - 3530, 3650, 6100, 6610,
7210, 7250, 7650 Motorola - C350, T720) Are all phones Java capable?
The latest phones that have been released in 2003 and late 2002, are
likely to be Java phones. You can refer this to the handset manual.
The MAIS UNDER THE AMA STUDY! THE SOFTWARE CONVERTS DICOM IMAGES ONTO A CHART SO CANCER CAN BE DETECTED
IN THE EARLY STAGE. SO, I WOULD LIKE TO MEET PEOPLE THAT WOULD LIKE TO PUT A
END TO CANCER! KENNETH LERTER HAYNES, MY INSPIRATION FOR FINDING THE
CURE PASSED THIS YEAR FORM CANCER.
*********************************************************** MEDICAL
IMAGING ANALYSIS SOFTWARE READS MRI,CT,AND PET SCANS
PATENT... COME JOIN US IN THE NEW ERROR OF EARLY CANCER DETECTION!
***********************************************************
Electronic
Acknowledgement Receipt EFS ID: 2596810 Application Number: 61014070
Confirmation Number: 9405 International Application Number: Title of
Invention: Medical Imaging Analysis and Diagnosis of MRI, CT, and PET
Scans First Named Inventor/Applicant Name: David H Kanecki
Correspondence Address: David Kanecki - P.O. Box 866 - Kenosha WI 53141
US 262-327-2605 david@kanecki.com
**********************************************************
********************************************************** Application
Type: Provisional Time Stamp: 22:27:17 Filing Date: Receipt Date:
16-DEC-2007 Attorney Docket Number: Filer Authorized By: Filer: David
Kanecki Payment information: Submitted with Payment no File Listing:
Document Number Document Description File Name File Size(Bytes)
/Message Digest Multi Part /.zip Pages (if appl.) 1 mias60patent.pdf
689925 yes 10 e09dc84986ef00f76a335f83e743ed70a f7789b4 Multipart
Description/PDF files in .zip description Document Description Start
End Provisional Cover Sheet (SB16) 1 1
Claims 2 10 Warnings: Information: 2 Fee Worksheet (PTO-06)
fee-info.pdf 8099 no 2 5858f081eaf1f9389b5dfa6990bec95b2 34c5450
Warnings: Information: Total Files Size (in bytes): 698024 This
Acknowledgement Receipt evidences receipt on the noted date by the
USPTO of the indicated documents, characterized by the applicant, and
including page counts, where applicable. It serves as evidence of
receipt similar to a Post Card, as described in MPEP 503. New
Applications Under 35 U.S.C. 111 If a new application is being filed
and the application includes the necessary components for a filing date
(see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54)
will be issued in due course and the date shown on this Acknowledgement
Receipt will establish the filing date of the application. National
Stage of an International Application under 35 U.S.C. 371 If a timely
submission to enter the national stage of an international application
is compliant with the conditions of 35 U.S.C. 371 and other applicable
requirements a Form PCT/DO/EO/903 indicating acceptance of the
application as a national stage submission under 35 U.S.C. 371 will be
issued in addition to the Filing Receipt, in due course. New
International Application Filed with the USPTO as a Receiving Office If
a new international application is being filed and the international
application includes the necessary components for an international
filing date (see PCT Article 11 and MPEP 1810), a Notification of the
International Application Number and of the International Filing Date
(Form PCT/RO/105) will be issued in due course, subject to
prescriptions concerning national security, and the date shown on this
Acknowledgement Receipt will establish the international filing date of
the application.
********************************************************** STUDY
RESULTS AS OF